Logo image of CTMX

CYTOMX THERAPEUTICS INC (CTMX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTMX - US23284F1057 - Common Stock

5.37 USD
-0.02 (-0.37%)
Last: 1/20/2026, 8:00:01 PM
5.54 USD
+0.17 (+3.17%)
Pre-Market: 1/21/2026, 5:17:36 AM
Fundamental Rating

4

Overall CTMX gets a fundamental rating of 4 out of 10. We evaluated CTMX against 525 industry peers in the Biotechnology industry. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability. CTMX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year CTMX was profitable.
  • In the past year CTMX has reported a negative cash flow from operations.
  • In the past 5 years CTMX reported 4 times negative net income.
  • CTMX had negative operating cash flow in 4 of the past 5 years.
CTMX Yearly Net Income VS EBIT VS OCF VS FCFCTMX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

  • CTMX's Return On Assets of 17.70% is amongst the best of the industry. CTMX outperforms 96.19% of its industry peers.
  • CTMX has a Return On Equity of 26.09%. This is amongst the best in the industry. CTMX outperforms 97.33% of its industry peers.
  • With an excellent Return On Invested Capital value of 15.67%, CTMX belongs to the best of the industry, outperforming 96.38% of the companies in the same industry.
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROIC 15.67%
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTMX Yearly ROA, ROE, ROICCTMX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K

1.3 Margins

  • Looking at the Profit Margin, with a value of 24.66%, CTMX belongs to the top of the industry, outperforming 94.67% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 20.46%, CTMX belongs to the top of the industry, outperforming 94.86% of the companies in the same industry.
Industry RankSector Rank
OM 20.46%
PM (TTM) 24.66%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTMX Yearly Profit, Operating, Gross MarginsCTMX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CTMX is still creating some value.
  • Compared to 1 year ago, CTMX has more shares outstanding
  • The number of shares outstanding for CTMX has been increased compared to 5 years ago.
  • CTMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CTMX Yearly Shares OutstandingCTMX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CTMX Yearly Total Debt VS Total AssetsCTMX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • CTMX has an Altman-Z score of 6.72. This indicates that CTMX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CTMX (6.72) is better than 77.14% of its industry peers.
  • There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.72
ROIC/WACC1.76
WACC8.88%
CTMX Yearly LT Debt VS Equity VS FCFCTMX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.64, CTMX perfoms like the industry average, outperforming 43.81% of the companies in the same industry.
  • A Quick Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
  • CTMX has a Quick ratio (3.64) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 3.64
CTMX Yearly Current Assets VS Current LiabilitesCTMX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 140.59% over the past year.
  • The Revenue for CTMX has decreased by -10.26% in the past year. This is quite bad
  • Measured over the past years, CTMX shows a quite strong growth in Revenue. The Revenue has been growing by 19.15% on average per year.
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%

3.2 Future

  • The Earnings Per Share is expected to decrease by -21.56% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -0.20% on average over the next years.
EPS Next Y-105.14%
EPS Next 2Y-73.24%
EPS Next 3Y-43.71%
EPS Next 5Y-21.56%
Revenue Next Year-31.15%
Revenue Next 2Y-41.74%
Revenue Next 3Y-24.21%
Revenue Next 5Y-0.2%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CTMX Yearly Revenue VS EstimatesCTMX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
CTMX Yearly EPS VS EstimatesCTMX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 13.10, which indicates a correct valuation of CTMX.
  • CTMX's Price/Earnings ratio is rather cheap when compared to the industry. CTMX is cheaper than 97.14% of the companies in the same industry.
  • CTMX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.94.
  • The Forward Price/Earnings Ratio is negative for CTMX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 13.1
Fwd PE N/A
CTMX Price Earnings VS Forward Price EarningsCTMX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CTMX indicates a rather cheap valuation: CTMX is cheaper than 93.14% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 26.78
CTMX Per share dataCTMX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

  • A cheap valuation may be justified as CTMX's earnings are expected to decrease with -43.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.24%
EPS Next 3Y-43.71%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for CTMX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CYTOMX THERAPEUTICS INC

NASDAQ:CTMX (1/20/2026, 8:00:01 PM)

Premarket: 5.54 +0.17 (+3.17%)

5.37

-0.02 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners77.94%
Inst Owner Change-0.12%
Ins Owners0.53%
Ins Owner Change-2.89%
Market Cap909.89M
Revenue(TTM)113.63M
Net Income(TTM)28.02M
Analysts84.29
Price Target7.21 (34.26%)
Short Float %15.77%
Short Ratio7.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.22%
Min EPS beat(2)-74.27%
Max EPS beat(2)98.72%
EPS beat(4)3
Avg EPS beat(4)88.28%
Min EPS beat(4)-74.27%
Max EPS beat(4)215.22%
EPS beat(8)7
Avg EPS beat(8)121.73%
EPS beat(12)10
Avg EPS beat(12)96.64%
EPS beat(16)11
Avg EPS beat(16)69.24%
Revenue beat(2)1
Avg Revenue beat(2)-12.98%
Min Revenue beat(2)-49.71%
Max Revenue beat(2)23.76%
Revenue beat(4)3
Avg Revenue beat(4)32.06%
Min Revenue beat(4)-49.71%
Max Revenue beat(4)92.34%
Revenue beat(8)7
Avg Revenue beat(8)44.02%
Revenue beat(12)10
Avg Revenue beat(12)36.04%
Revenue beat(16)10
Avg Revenue beat(16)9.74%
PT rev (1m)0%
PT rev (3m)22.22%
EPS NQ rev (1m)-24.85%
EPS NQ rev (3m)-51.87%
EPS NY rev (1m)-51.31%
EPS NY rev (3m)-160.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.16%
Valuation
Industry RankSector Rank
PE 13.1
Fwd PE N/A
P/S 8.01
P/FCF N/A
P/OCF N/A
P/B 8.47
P/tB 8.59
EV/EBITDA 26.78
EPS(TTM)0.41
EY7.64%
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.67
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.42
Profitability
Industry RankSector Rank
ROA 17.7%
ROE 26.09%
ROCE 19.83%
ROIC 15.67%
ROICexc N/A
ROICexgc N/A
OM 20.46%
PM (TTM) 24.66%
GM N/A
FCFM N/A
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 7.74%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 3.64
Altman-Z 6.72
F-Score5
WACC8.88%
ROIC/WACC1.76
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
EPS Next Y-105.14%
EPS Next 2Y-73.24%
EPS Next 3Y-43.71%
EPS Next 5Y-21.56%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
Revenue Next Year-31.15%
Revenue Next 2Y-41.74%
Revenue Next 3Y-24.21%
Revenue Next 5Y-0.2%
EBIT growth 1Y246.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.27%
EBIT Next 3Y-120.2%
EBIT Next 5YN/A
FCF growth 1Y-99.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.53%
OCF growth 3YN/A
OCF growth 5YN/A

CYTOMX THERAPEUTICS INC / CTMX FAQ

What is the fundamental rating for CTMX stock?

ChartMill assigns a fundamental rating of 4 / 10 to CTMX.


What is the valuation status for CTMX stock?

ChartMill assigns a valuation rating of 3 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.


What is the profitability of CTMX stock?

CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 4 / 10.


What is the financial health of CYTOMX THERAPEUTICS INC (CTMX) stock?

The financial health rating of CYTOMX THERAPEUTICS INC (CTMX) is 7 / 10.


What is the expected EPS growth for CYTOMX THERAPEUTICS INC (CTMX) stock?

The Earnings per Share (EPS) of CYTOMX THERAPEUTICS INC (CTMX) is expected to decline by -105.14% in the next year.